Clinical Trials Arena January 2, 2025
Since 2017, the Asia-Pacific surpassed North America in rare disease trials and has since maintained dominance in this space.
According to GlobalData’s Clinical Trials Database, non-industry sponsored trials lead rare disease indications, accounting for 55.6% of all trials since 2004.
Rare disease indications can focus on specific patient populations, which may not provide enough financial incentive for pharmaceutical companies to invest heavily in research and development in these areas. Non-industry sponsors, such as academic institutions or government organisations, may step in to fill this gap due to their focus on advancing scientific knowledge and public health rather than profit.
Non-industry sponsors may additionally be more experienced at navigating incentives or may receive grants and funding specifically aimed at rare disease...
Today's Sponsors
Today's Sponsor